China's largest private oncology hospital group — where cutting-edge technology meets compassionate cancer care.
8 Provinces · 13 Cities
HKEX: 6078.HK · Since 2009
HYGEIA Healthcare Holdings Limited is China's largest private oncology-focused hospital group, listed on the Hong Kong Stock Exchange (6078.HK) since June 29, 2020. Founded in 2009, we have grown through a strategic combination of organic expansion and targeted acquisitions to build a nationwide network of 16 hospitals across 8 provinces and 13 cities.
With 12,000+ hospital beds and 450 million annual patient visits (2024), HYGEIA is the premier destination for cancer patients seeking world-class treatment at accessible costs. Our vertical integration — from proprietary radiotherapy equipment R&D through clinical care delivery — ensures quality, efficiency, and affordability unmatched by any other provider.
Making healthcare warmer, making life healthier. We believe every cancer patient deserves access to high-quality, compassionate care — regardless of geography or economic circumstance.
Speak truth. Do practical things. Be honest and trustworthy. These principles guide every interaction with our patients, partners, and communities.
From a single radiotherapy technology company to China's largest oncology hospital group.
Acquired GammaStar Technology (伽玛星科技), gaining proprietary stereotactic radiotherapy equipment manufacturing capability. This marked HYGEIA's entry into oncology.
Launched radiotherapy center services with the Xuanwei Radiotherapy Center as the first facility, pioneering the integrated equipment + service model.
Acquired Handan Renhe Hospital, marking the beginning of HYGEIA's hospital network and the transition from equipment provider to integrated healthcare operator.
Listed on Hong Kong Stock Exchange (6078.HK) on June 29, 2020, providing capital for accelerated expansion and cementing HYGEIA's position as China's oncology leader.
In 2023, HYGEIA completed the landmark acquisition of Chang'an Hospital in Xi'an for ¥1.66 billion — the group's first tertiary hospital in a provincial capital, marking a strategic expansion into higher-tier cities.
16 hospitals across 8 provinces and 13 cities, bringing world-class cancer care closer to patients throughout China.
HYGEIA's unique advantage lies in its vertical integration — from radiotherapy equipment R&D to clinical treatment delivery.
陀螺旋转式钴60立体定向放射治疗系统
Self-developed stereotactic radiotherapy system for precise treatment of head and body tumors.
Through our wholly-owned subsidiary Shanghai GammaStar Technology Co., Ltd. (上海伽玛星科技发展有限公司), HYGEIA independently designs, manufactures, and deploys the Gyro Knife stereotactic radiotherapy system — a patented, high-tech medical device for treating head and body tumors.
This vertical integration creates a powerful synergy: we control the technology, we operate the hospitals, and we deliver the treatment. The result is superior quality control, faster technology iteration, and cost advantages that directly benefit our patients.
Learn About Gyro Knife